CONTEXT

At present, four complexes based on cis-platin are used for their alkylating properties as anti-cancer drugs (Oxaliplatin, Nedaplatin, Cisplatin and Carboplatin). However, those molecules present high toxicity limiting their use in cancer therapy.

TECHNICAL DESCRIPTION

The invention describes new series of bioorganometallic cyclic complexes which are endowed with high and original antiproliferative properties. These molecules induce a selective apoptosis of cancerous cells and offer therefore an important therapeutic advance in the treatment of cancers.

DEVELOPMENT STAGE

The inventors have conducted in vitro essays. They are preparing to lauch in vivo essays.

BENEFITS

The advantage of this technology is that these bioorganometallic molecules induce apoptosis of cancerous cells at a very low IC50 (10 nanoMol) without affecting healthy cells. This selectivity associated to the absence of toxicity present a very promising profile for the development of efficient anticancer drugs.

INDUSTRIAL APPLICATIONS

The application of this invention concerns development of new anti-tumor compounds presenting a high therapeutic index.